Bill

HR 1532

Scientific EXPERT Act of 2025

119th Congress Introduced by Gus Bilirakis and 5 co-sponsors

The Scientific EXPERT Act of 2025 ensures external scientific experts review therapeutics, enhancing safety and effectiveness for patients and healthcare providers.

Introduced in House

WeVote Research Nonpartisan

Bill Summary · HR 1532

Summary of HR 1532 - Scientific EXPERT Act of 2025

Overview

The Scientific External Process for Educated Review of Therapeutics Act of 2025, commonly referred to as the Scientific EXPERT Act of 2025, was introduced in the House of Representatives on February 24, 2025. The bill aims to enhance the review process for therapeutics by establishing a structured external review mechanism that incorporates scientific expertise.

Purpose and Intent

The primary purpose of the Scientific EXPERT Act is to improve the evaluation of therapeutic products by ensuring that the review process is informed by external scientific experts. This initiative seeks to bolster the credibility and effectiveness of therapeutic assessments, ultimately leading to better health outcomes and more efficient regulatory practices.

Key Provisions

While the full text of the bill is not provided, the following key provisions can be anticipated based on the title and intent:

External Review Process: Establishment of a formalized process for external scientific experts to review therapeutic products before they are approved for public use.
Criteria for Expert Selection: Guidelines for selecting qualified experts who will participate in the review process, ensuring a diverse range of scientific perspectives.
Transparency Measures: Implementation of transparency protocols to make the review process accessible and understandable to stakeholders, including healthcare providers and the public.
Feedback Mechanism: Creation of a system for incorporating feedback from the external review into the regulatory decision-making process.

Affected Parties

The Scientific EXPERT Act would primarily impact:

Regulatory Agencies: Such as the Food and Drug Administration (FDA), which would be responsible for integrating the external review process into their existing frameworks.
Pharmaceutical and Biotech Companies: These entities would need to adapt to the new review requirements when seeking approval for their therapeutic products.
Healthcare Providers and Patients: Improved therapeutic evaluations could lead to safer and more effective treatment options, benefiting both healthcare providers and patients.

Legislative Actions and Timeline

Introduced: February 24, 2025
Referred to Committee: The bill has been referred to the House Committee on Energy and Commerce for further consideration.

Related Legislation

The Scientific EXPERT Act of 2025 has a companion bill, S 822, which is being considered in the Senate. This indicates a potential for bipartisan support and a collaborative approach to enhancing therapeutic review processes across both chambers of Congress.

Conclusion

The Scientific EXPERT Act of 2025 represents a significant step toward improving the regulatory landscape for therapeutics by emphasizing the importance of scientific expertise in the review process. As the bill progresses through the legislative process, it will be crucial to monitor its developments and potential implications for public health and safety.

Compiled from official sources — confirm details with the bill’s official record.